Liquiritin demonstrates significant potential as a therapeutic agent for psoriasis in both in vitro (using TNF-α-stimulated HaCaT keratinocytes) and in vivo (IMQ-induced psoriasis-like mouse model) settings, where it effectively inhibits psoriasis progression. This evidence concerns the gene TNF and psoriasis.